Free Trial

Regal Partners Ltd Buys 2,286,285 Shares of Opthea Limited Unsponsored ADR (NASDAQ:OPT)

Opthea logo with Medical background

Key Points

  • Regal Partners Ltd increased its stake in Opthea Limited Unsponsored ADR by 78.6% in the first quarter, totaling 5,193,688 shares worth approximately $17.71 million.
  • Institutional investors and hedge funds own around 55.95% of Opthea's stock, highlighting significant interest from the investment community.
  • Opthea's shares recently opened at $3.41 and have a 52-week trading range between $1.79 and $6.30.
  • Need better tools to track Opthea? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Regal Partners Ltd increased its position in shares of Opthea Limited Unsponsored ADR (NASDAQ:OPT - Free Report) by 78.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,193,688 shares of the company's stock after purchasing an additional 2,286,285 shares during the period. Opthea comprises about 1.8% of Regal Partners Ltd's investment portfolio, making the stock its 16th largest position. Regal Partners Ltd owned about 3.37% of Opthea worth $17,710,000 at the end of the most recent reporting period.

Separately, Citadel Advisors LLC bought a new stake in shares of Opthea in the fourth quarter worth about $79,000. Institutional investors own 55.95% of the company's stock.

Opthea Stock Up 7.2%

Shares of Opthea stock traded up $0.23 during trading hours on Friday, hitting $3.41. The company's stock had a trading volume of 3,000 shares, compared to its average volume of 38,738. The stock has a 50 day moving average of $3.41 and a 200 day moving average of $3.71. Opthea Limited Unsponsored ADR has a 12 month low of $1.79 and a 12 month high of $6.30.

About Opthea

(Free Report)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Featured Articles

Institutional Ownership by Quarter for Opthea (NASDAQ:OPT)

Should You Invest $1,000 in Opthea Right Now?

Before you consider Opthea, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.

While Opthea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines